Femasys (FEMY)

A central product in the portfolio is FemaSeed, an intratubal insemination technology designed to deliver sperm directly into a fallopian tube as an infertility treatment option. Femasys also markets FemVue, a diagnostic product used with ultrasound to assess whether the fallopian tubes are open, which is an important part of fertility evaluation. These products position the company in areas where patients and clinicians may seek alternatives before moving to more complex or expensive assisted reproductive technologies.

The company’s development pipeline includes FemBloc, a non-surgical permanent birth control candidate intended for in-office use. Femasys also offers or develops complementary tools such as FemCerv for cervical tissue sampling, along with FemCath and FemChec, which support procedures in its reproductive health platform.

Femasys generates most of its revenue in the United States, with additional activity in international markets. As a small medical technology company, its prospects depend on regulatory progress, physician adoption, reimbursement, clinical evidence, and the ability to scale commercial distribution. Its distinctive focus is the creation of office-based technologies for underserved areas of women’s healthcare.